I work for a very large company that is owned by an OPEC country. Money is EXTREMLY tight because of $40 oil. $20 oil will bankrupt them within a couple of years. Again, IMO from what I see and read.
How ever, I do agree mostly with your senario of GE picking the corps of DRYS ships clean for his private companies including the ORIG shares from DRYS.
OPEC contries will go broke with $20 oil. No one can stay in business pumping oil for $20/barrel
Just my opinion. Be a leader, not a follower of other peoples' headlines.
Think about it. GE has taken the best from DRYS for his private company. Why would he roll all the good equipment back into that public company (DRYS)? JMO
How do you figure the Nasdaq issue is resolved? It only gave DRYS a 6 month extension to get the PPS over a $1.00
Really? Is that what "disposition" means? Glad you told me. He sold ~ $16,500 worth of stock. Probally needed a little cha ching for the holidays...Oh, let me explain, (~) means approximately and "cha ching" means drinking money...LOL
A new study of more than 25,000 men has uncovered four new genetic variants associated with increased risk of testicular cancer.
Testing for these variants combined with all 21 previously identified using genetic sequencing identified men with a 10-fold higher risk of testicular cancer than the population average.
The research, led by scientists at The Institute of Cancer Research, London, is the largest study to date of the genetics of testicular germ cell tumours - the most common cancer in young men.
The study is published in the journal Nature Communications today (Tuesday), and is funded by the Movember Foundation, The Institute of Cancer Research (ICR) and Cancer Research UK.
Researchers discovered the four new variants through analysing the DNA of 6,059 patients with testicular cancer, and comparing it with the DNA of 19,094 people without the disease.
The sizes of the effects of some of the genetic variants associated with testicular cancer risk are quite high - compared with breast and prostate cancer, for example, where most variants each have only a very small effect. A man in the top one per cent of genetic risk had a five per cent lifetime risk of developing testicular cancer, more than 10 times higher than that of the average man.
There are no current treatment options that target specific genetic mutations in testicular cancer, and standard treatment with platinum-based chemotherapy has a high success rate. That means that the more likely application of genetic testing in testicular cancer is in diagnosing the level of risk in men yet to develop it, rather than in matching patients to specific treatments.
However, understanding the genetic variants underlying susceptibility to testicular cancer also helps us understand the biology of the disease, which may in due course inform development of new targeted therapies that could be effective in patients resistant to platinum chemotherapy.
Carrying two copies of a single-letter change in the DNA of chromosome 16 led to a 35 per cent increase in activity of the gene GSPT1¬ in men with testicular cancer, compared with those without. This gene has a role in controlling cell division and has been shown to have increased activity in cancers of the breast, stomach and prostate.
"DryShips Inc. Announces Listing Transfer to Nasdaq Capital Market"
This gave them six additional months to get the PPS over $1.00
SAN DIEGO, Oct. 19, 2015 /PRNewswire/ -- Sequenom, Inc., a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into a clinical collaboration with the University of Colorado Denver, School of Medicine (CU School of Medicine). Under this collaboration, CU School of Medicine will explore the utility of Sequenom's research use only (RUO) liquid biopsy assay to determine whether ctDNA profiling can be used to monitor treatment response and relapse in melanoma patients. This technology has the potential to overcome the challenges and limitations associated with current methods to monitor treatment response such as invasive biopsies and repeated imaging studies.
"In just the last few years, we have made significant progress in the treatment of melanoma patients in whom the disease has progressed beyond the skin to involve internal organs. I believe that the ability to match patients to new treatment options and to monitor their response with a simple blood test will yield significant clinical benefit," said William Robinson, MD, PhD, Professor, Division of Medical Oncology, Rella and Monroe Rifkin Endowed Chair, University of Colorado School of Medicine. "We anticipate that the collaboration with Sequenom will allow us to closely monitor treatment response and the emergence of resistance mutations over time and make changes or adjustments in treatment much earlier than can be done currently."
Sequenom is currently developing an RUO assay with an initial focus on the detection and molecular profiling of late stage non-hematologic malignancies, where tissue biopsies are not available or too risky to obtain. The assay will cover a breadth of cancer types by analyzing over 100 cancer-related genes that are associated with a Food and Drug Administration (FDA)-approved drug treatment, included in professional society guidelines, linked to targeted therapies currently in clinical trials, or part of well-documented cancer pathways.
"Liquid biopsy has many potential applications for a variety of cancers," said Daniel Grosu, M.D., Chief Medical Officer at Sequenom. "This is our first collaborative study focusing on melanoma, which expands the range of cancers and clinical care settings that we are exploring with this novel technology. We are uniquely positioned to leverage our strong expertise in testing circulating cell-free DNA to move liquid biopsy from a research concept to routine clinical practice in oncology."
Scottrade shows SQNM 58% of the shares owned by Investment Managers. They are also showing CAMBER CAPITAL MANAGEMENT's last purchase as an "insider buy"??
Let’s move on to Sequenom Inc, which Camber Capital Management, managed by Stephen Dubois, is as bullish as ever on. It’s been about 16 months since we reported that Dubois’s healthcare-focused firm had built its stake in the genome-focused life sciences company to 6.3 million shares. Since then it had gradually added even more shares to its haul, owning an even 9.0 million shares on June 30 of this year. However, it’s made its biggest move yet since then, reporting ownership of 15.4 million shares in today’s filing, giving it a 13% stake in the company.
Camber clearly feels very strongly about the work Sequenom Inc. is doing, even if the broader market isn’t so sure yet. Sequenom’s shares have been cut in half over the past 16 months. Shares are also down by 49% this year, having strongly trended down from May 7 onward, after the company released its first quarter financial results. In addition to the results coming in below analysts’ expectations, Wedbush also downgraded the stock to ‘Neutral’, which led to shares diving by 15% on May 7.
The investors in our database largely maintained their Sequenom Inc. holdings during the second quarter, with 13 investors long Sequenom at the start and end of the quarter, and the value of their holdings falling at about an equal pace as the stock, meaning there was limited collective movement of shares. Funds we track held 22.30% of its shares. Atop that list was William Leland Edwards’ Palo Alto Investors with 10.02 million shares, which has now been surpassed by Camber’s enhanced position.